Glymetia (Metformin Hydrochloride, Linagliptin)

Glymetia is indicated for the treatment of type 2 diabetes mellitus in adults when monotherapy with either component does not achieve adequate glycemic control.

• Improves fasting and post‑prandial blood glucose when used with diet and exercise.
• Provides combined action of metformin (decreases hepatic glucose output) and linagliptin (enhances incretin effect).
• May be used as an alternative to separate metformin and DPP‑4 inhibitor tablets.
• Can be considered in patients with renal impairment where metformin dose needs adjustment.
• Supports long‑term glycemic management as part of a comprehensive diabetes care plan.

The safety profile of Glymetia reflects the combined effects of metformin and linagliptin, with side effects ranging from mild to rare serious events.

Common

• Gastrointestinal upset such as nausea, diarrhea, or abdominal discomfort.
• Upper respiratory tract infection symptoms, including sore throat or nasal congestion.
• Headache or dizziness.
• Mild hypoglycemia, especially when taken with other glucose‑lowering agents.

Serious

• Lactic acidosis, a rare but life‑threatening condition associated with metformin accumulation.
• Severe hypersensitivity reactions, including skin rash, angioedema, or anaphylaxis.
• Pancreatitis, presenting as persistent abdominal pain and elevated enzymes.
• Hepatic dysfunction indicated by jaundice or abnormal liver tests.

Before initiating Glymetia, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal function; metformin is contraindicated in severe renal impairment.
• Review hepatic status, as liver disease can predispose to lactic acidosis.
• Evaluate for a history of heart failure or unstable cardiovascular disease.
• Use caution in patients with a known allergy to metformin, linagliptin, or excipients.
• Monitor for signs of hypoglycemia when combined with insulin or sulfonylureas.
• Consider pregnancy status; the safety of Glymetia during pregnancy has not been established.

Glymetia may interact with other medicines, altering its efficacy or increasing the risk of side effects; certain combinations should be avoided while others require careful monitoring.

Avoid

• Concomitant use with iodinated contrast agents in patients with reduced renal function, because metformin accumulation can precipitate lactic acidosis.
• Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that markedly increase linagliptin plasma levels.

Use with caution

• Combination with insulin, sulfonylureas, or other glucose‑lowering drugs may heighten the risk of hypoglycemia; dose adjustments may be needed.
• Use with loop or thiazide diuretics, as well as ACE inhibitors or ARBs, may affect renal function and alter metformin clearance.
• Co‑administration with hepatic enzyme inducers (e.g., rifampicin, carbamazepine) may reduce linagliptin exposure and diminish glycemic control.